Stay updated on Subcutaneous vs. Intravenous Daratumumab in Myeloma Clinical Trial

Sign up to get notified when there's something new on the Subcutaneous vs. Intravenous Daratumumab in Myeloma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Subcutaneous vs. Intravenous Daratumumab in Myeloma Clinical Trial page

  1. Check
    2 days ago
    No Change Detected
  2. Check
    9 days ago
    Change Detected
    Summary
    The web page has updated its version from v2.15.0 to v2.15.2 and changed the date from April 1, 2025, to April 29, 2025.
    Difference
    0.7%
    Check dated 2025-04-30T13:42:32.000Z thumbnail image
  3. Check
    16 days ago
    No Change Detected
  4. Check
    24 days ago
    Change Detected
    Summary
    The page has been updated to reflect a new version, changing from v2.14.4 to v2.15.0.
    Difference
    1.0%
    Check dated 2025-04-16T01:21:12.000Z thumbnail image
  5. Check
    31 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.3 to version 2.14.4.
    Difference
    0.3%
    Check dated 2025-04-08T19:52:12.000Z thumbnail image
  6. Check
    74 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    5%
    Check dated 2025-02-24T16:27:11.000Z thumbnail image
  7. Check
    81 days ago
    Change Detected
    Summary
    The date '2024-03-13' has been removed, and '2025-02-12' has been added to the page.
    Difference
    0.9%
    Check dated 2025-02-17T12:45:24.000Z thumbnail image
  8. Check
    88 days ago
    Change Detected
    Summary
    The page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for the Help Desk.
    Difference
    6%
    Check dated 2025-02-10T09:16:56.000Z thumbnail image

Stay in the know with updates to Subcutaneous vs. Intravenous Daratumumab in Myeloma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Subcutaneous vs. Intravenous Daratumumab in Myeloma Clinical Trial page.